GSK has another adjuvant, MPL, which they acquired when they bought out Corixa...for 300 million.
MPL and QS-21 are in Bill Gates' Malaria Vaccine. That vaccine did not work until they added QS-21 to it.
QS-21 is in three other vaccines made by GSK in Phase 3 development.
It is in at least 12 other vaccines in clinical trials, also.
I would think QS-21 is worth 400 million which would give us a share price of 16.00.
...and, here we sit at 4.50.
Interesting. I found where the CEO, Armen Garo, in a webcast on AGEN's website on October 21st stated future projections of peak sales on QS-21 of "hundreds of millions of dollars" annually. I was thinking $200 million (one years' annual sales) X 5X's sales = $1 billion. But what do I know.
I like hearing everyone's opinions and getting good solid information about companies. It seems GSK protected their investment by purchasing a "First Right to Negotiate". I am interested in hearing as many valuations as possible. Any more thoughts out there?